Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.

Abstract

IMPORTANCE OF THE FIELD:

TNF-alpha inhibitors such as etanercept have been used for psoriasis for years. A fairly well defined efficacy and safety profile has developed. A new biologic agent, ustekinumab, an IL-12 and IL-23 inhibitor, has recently been released in the US for the treatment of moderate-to-severe psoriasis. The purpose of this article is to compare the efficacy and safety profiles of ustekinumab and etanercept.

AREAS COVERED IN THIS REVIEW:

We examined safety and efficacy data regarding ustekinumab and etanercept from clinical reports, a head-to-head trial, review articles, and databases and registries from the last 20 years.

WHAT THE READER WILL GAIN:

Evidence is reviewed about the efficacy for the treatment of psoriasis as well as the safety profiles for both agents, ustekinumab and etanercept.

TAKE HOME MESSAGE:

Both drugs have data to confirm efficacy and safety in patients with moderate-to-severe psoriasis in the short-term. The limited long-term data on the safety profile of ustekinumab requires careful judgment on the clinician's part, weighing well-defined benefits and potential unknown risks.

• Authors: Elizabeth E Uhlenhake, Steven R Feldman
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 10 Issue 7 Pg. 1105-12 (Jul 2010) ISSN: 1744-7682 [Electronic] England
• PMID: 20446825 (Publication Type: Journal Article, Review)

Chemical References

• Anti-Inflammatory Agents
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Immunoglobulin G
• Immunosuppressive Agents
• Receptors, Tumor Necrosis Factor
• Ustekinumab
• Etanercept

Topics

• Anti-Inflammatory Agents (adverse effects, therapeutic use)
• Antibodies, Monoclonal (adverse effects, therapeutic use)
• Antibodies, Monoclonal, Humanized
• Etanercept
• Evidence-Based Medicine
• Humans
• Immunoglobulin G (adverse effects, therapeutic use)
• Immunosuppressive Agents (adverse effects, therapeutic use)
• Patient Selection
• Psoriasis (drug therapy, immunology)
• Receptors, Tumor Necrosis Factor (therapeutic use)
• Risk Assessment
• Severity of Illness Index
• Treatment Outcome
• Ustekinumab